Biosceptre publishes a clinical study of topical drug BIL010t as therapy for BCCBiosceptre2019-12-12T15:33:56+11:00March 3rd, 2017|News|Read More
Biosceptre appoints Sir Greg Winter as Chairman of the BoardBiosceptre2016-12-01T02:37:32+11:00December 1st, 2016|News|Read More
Biosceptre Interviewed by Pharmaventures at Sachs Associates Conference, BaselBiosceptre2019-12-12T15:21:10+11:00October 27th, 2016|News|Read More
Professor Francesco Di Virgilio joins Biosceptre Scientific Advisory BoardBiosceptre2020-05-12T10:35:05+10:00July 27th, 2016|News|Read More
Biosceptre presents at leading Immuno-oncology Investment Conference in ChicagoBiosceptre2019-12-12T15:11:51+11:00June 13th, 2016|News|Read More
Sir Gregory Winter joins Biosceptre BoardBiosceptre2019-12-12T15:01:31+11:00May 30th, 2016|News|Read More
Biosceptre Wins Funding from the UK Government-Backed, SMART Award to Develop Novel Cancer Diagnostic and Therapeutic TargetsBiosceptre2016-02-25T05:04:45+11:00February 25th, 2016|News|Read More
Biosceptre appoints new Chief Scientific OfficerBiosceptre2014-10-20T09:00:29+11:00October 20th, 2014|Corporate|Read More
Biosceptre announces positive Phase I results for BIL-010t to treat Basal Cell CarcinomaBiosceptre2014-07-23T07:00:42+10:00July 23rd, 2014|Clinical|Read More
